Home » Stocks » RNA

Avidity Biosciences, Inc. (RNA)

Stock Price: $20.08 USD -0.68 (-3.28%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $20.49 +0.41 (2.04%) Jul 29, 4:05 PM
Market Cap 733.87M
Revenue (ttm) 8.13M
Net Income (ttm) -62.11M
Shares Out 37.62M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $20.08
Previous Close $20.76
Change ($) -0.68
Change (%) -3.28%
Day's Open 20.69
Day's Range 19.95 - 20.97
Day's Volume 98,161
52-Week Range 18.85 - 37.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LA JOLLA, Calif., May 19, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleot...

2 months ago - PRNewsWire

LA JOLLA, Calif., May 12, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleot...

2 months ago - PRNewsWire

LA JOLLA, Calif., May 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleoti...

2 months ago - PRNewsWire

LA JOLLA, Calif., March 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...

4 months ago - PRNewsWire

LA JOLLA, Calif., March 15, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...

4 months ago - PRNewsWire

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other stocks mentioned: AVIR, JNJ, LEGN, LLY, NKTX, RHHBY
5 months ago - GuruFocus

LA JOLLA, Calif., Dec. 22, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

7 months ago - PRNewsWire

LA JOLLA, Calif., Dec. 21, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

7 months ago - PRNewsWire

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

Other stocks mentioned: ABNB, AI, AZEK, DASH, GBIO, PCVX, UCL ...
7 months ago - Seeking Alpha

LA JOLLA, Calif., Nov. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

8 months ago - PRNewsWire

LA JOLLA, Calif., Sept. 28, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...

10 months ago - PRNewsWire

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.

10 months ago - PRNewsWire

SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.

11 months ago - PRNewsWire

SAN DIEGO, July 27, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Co...

1 year ago - PRNewsWire

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, FMTX, IMRA, KROS, PCVX, RPTX, XBI ...
1 year ago - CNN Business

SAN DIEGO, June 16, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Co...

1 year ago - PRNewsWire

Shares of Avidity Biosciences Inc. RNA, +55.66% soared 50% in their trading debut on the Nasdaq on Friday after pricing at the top of their initial public offering range, a sign of heightened interest f...

1 year ago - Market Watch

Avidity Biosciences Inc. RNA, , a biotech the specializes in treatments for muscular disorders, priced its initial public offering at $18 a share late Thursday, the high end of its price range.

1 year ago - Market Watch

SAN DIEGO, June 11, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Con...

1 year ago - PRNewsWire

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable... [Read more...]

Industry
Biotechnology
IPO Date
Jun 12, 2020
Stock Exchange
NASDAQ
Ticker Symbol
RNA
Full Company Profile

Financial Performance

In 2020, RNA's revenue was $6.79 million, an increase of 192.67% compared to the previous year's $2.32 million. Losses were -$44.36 million, 79.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is 45.75, which is an increase of 127.84% from the latest price.

Price Target
$45.75
(127.84% upside)
Analyst Consensus: Strong Buy